Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | GSK3A | P49840 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12406684 | 0.71 | BRD4 (0.36) | CASP3CRBNKDM4EGSK3AGSK3B | |
| SCHEMBL46223 | 0.71 | ALDH1A1 (0.38) | CASP3KDM4EGSK3AGSK3BMGLL | |
| SCHEMBL6850987 | 0.69 | GSK3A (0.44) | CASP3KDM4EGSK3AGSK3BMGLL | |
| SCHEMBL84388 | 0.69 | GSK3A (0.35) | CRBNKDM4EHTTGSK3AGSK3B | |
| SCHEMBL18058915 | 0.69 | CASP3 (0.34) | CASP3 | |
| SCHEMBL10401009 | 0.69 | GSK3A (0.35) | CASP3GSK3AGSK3BMGLL | |
| SCHEMBL8271652 | 0.67 | — | — | |
| SCHEMBL12895935 | 0.65 | ALDH1A1 (0.34) | CASP3GSK3AGSK3BMGLL | |
| Hydrochloric Acid SCHEMBL22443373 | 0.65 | — | — | |
| SCHEMBL24668614 | 0.64 | CRBN (0.32) | CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9598418-B2 | Substituted phthalazin-1 (2H)-one derivatives as selective inhibitors of poly (ADP-ribose) polymerase-1 | CADILA HEALTHCARE LIMITED (IN) | 2017-03-21 | — | — | US | disclosed |
| US-9598418-B2 | Substituted phthalazin-1 (2H)-one derivatives as selective inhibitors of poly (ADP-ribose) polymerase-1 | CADILA HEALTHCARE LIMITED (IN) | 2017-03-21 | — | — | US | disclosed |
| US-20150291603-A1 | SUBSTITUTED PHTHALAZIN-1 (2H)-ONE DERIVATIVES AS SELECTIVE INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE-1 | CADILA HEALTHCARE LIMITED (IN) | 2015-10-15 | — | — | US | disclosed |
| US-20150291603-A1 | SUBSTITUTED PHTHALAZIN-1 (2H)-ONE DERIVATIVES AS SELECTIVE INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE-1 | CADILA HEALTHCARE LIMITED (IN) | 2015-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291603-A1 | SUBSTITUTED PHTHALAZIN-1 (2H)-ONE DERIVATIVES AS SELECTIVE INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE-1 | PARP1, PARP11, PARP2 | CASP3 1718/4885CRBN 3612/4885KDM4E 3427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.